Trial · NCT01634347
Memory Reconsolidation Blockade for Treating Drug Addiction
NCT01634347, Phase 2, Completed, Douglas Mental Health University Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Memory Reconsolidation Blockade for Treating Drug Addiction. Trials, record NCT01634347. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01634347
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Memory Reconsolidation Blockade for Treating Drug Addiction
- NCT number
- NCT01634347
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 17 participants, actual
- Lead sponsor
- Douglas Mental Health University Institute
- Conditions
- Substance Dependence
- Interventions
- Propranolol and memory reactivation, Placebo and memory reactivation
- First posted
- 2012-07-06
- Last updated
- 2017-05-15
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Substance craving scales | Weeks 3 or 6 | The craving scales ask about current craving for substances. Items for the questionnaires represent distinct conceptualizations of substance craving: (1) desire to use; (2) anticipation of positive outcomes from use; (3) anticipation of relief from withdrawal symptoms or relief from negative mood; (4) intention and planning to use; (5) lack of control over use. |
| Secondary | Number of days in a drug or alcohol addiction rehabilitation treatment program | Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline | |
| Secondary | Addiction severity | Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline | |
| Secondary | Rates of successfully completing a drug or alcohol rehabilitation program | Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline | |
| Secondary | Rates of planned or unplanned departure and expulsion from a drug or alcohol rehabilitation program | Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline | |
| Secondary | Frequency and intensity of drug or alcohol cravings | Once or twice a week for a 3-to-6 week period | |
| Secondary | Brief psychiatric rating scale | Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline | |
| Secondary | Rates of relapse of drug or alcohol dependence a drug or alcohol rehabilitation program. | Once or twice a week for a 3-to-6 week period, as well as at 4 months post-baseline | |
| Secondary | Rates of adverse events | From baseline to 28 days after the last administration of study medication |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01634347
GET https://conductscience.org/api/trials/v1/NCT01634347/registered